Sort   by:  
 Page size 
MetabolomicsPeroxin Pex8 couples stress responses, antifungal tolerance and virulence regulation in Candida albicans

Candida albicans, a World Health Organization critical-priority fungal pathogen, represents the predominant cause of candidemia. Therapeutic failure is sometimes driven by antifungal tolerance, a phenotype distinct from resistance, whose underlying mechanisms remain incompletely defined....

2026-03-12 | MTBLS13170 | MetaboLights
MetabolomicsBioinspired Rhamnolipid Protects Wheat Against Zymoseptoria tritici Through Mainly Direct Antifungal Activity and Without Major Impact on Leaf Physiology

Rhamnolipids (RLs), glycolipids biosynthesized by the Pseudomonas and Burkholderia genera, are known to display various activities against a wide range of pathogens. Most previous studies on RLs focused on their direct antimicrobial activity, while only a few reports described t...

2022-06-21 | MTBLS4542 | MetaboLights
MetabolomicsMechanistic profiling of Bifemetstrobin against the tea anthracnose pathogen and candidate evaluation of an amine oxidase target

Tea anthracnose caused by Glomerella cingulata threatens yield and quality, while resistance to legacy fungicides highlights the need for new modes of action. We characterized the antifungal activity and mechanism of bifemetstrobin against G. cingulata by combining efficacy assays with cell ...

2026-03-13 | MTBLS13992 | MetaboLights
MetabolomicsMechanistic profiling of Bifemetstrobin against the tea anthracnose pathogen and candidate evaluation of an amine oxidase target
Tea anthracnose caused by Glomerella cingulata threatens yield and quality, while resistance to legacy fungicides highlights the need for new modes of action. We characterized the antifungal activity and mechanism of bifemetstrobin against G. cingulata by combining efficacy assays with cell biology ...
2026-04-24 | MTBLS14357 | MetaboLights
MetabolomicsMetabolomic Profiling of Non-target Metabolites in Streptomyces sp. LZZY-S40
This study aimed to characterize the non-targeted metabolite profile of Streptomyces sp. LZZY-S40 to explore its potential for producing bioactive secondary metabolites. The strain LZZY-S40 was cultivated on ISP 3 agar plates at 28°C for 7 days. Spores were harvested and inoculated into 250 mL Erlen...
2026-03-29 | MTBLS14181 | MetaboLights
ProteomicsProteomics reveals that the antifungal activity of fenbendazole against Cryptococcus neoformans requires protein kinases.
Cryptococcus neoformans is responsible for over 100,000 deaths annually, and the treatment of this fungal disease is expensive and not consistently effective. Unveiling new therapeutic avenues is crucial. Previous studies have suggested that the anthelmintic drug fenbendazole is an affordable and n...
ORGANISM(S): Cryptococcus neoformans var. grubii serotype A (strain H99 / ATCC 208821 / CBS 10515 / FGSC 9487) (Filobasidiella neoformans var. grubii) 
2024-05-21 | PXD047041 | Pride
Cryptococcus neoformans  antifungal activity  fenbendazole  proteomics  protein kinases 
TranscriptomicsIn depth characterization of the activity of a novel synthetic macrocyclic antifungal compound
The systemic infections by peptogenous fungi member of the genera Candida and Aspergillus represent a serious threat for public health. During previous research we have successfully identified a family of compounds active against different Candida spp. including strains resistant to antifungal drugs...
ORGANISM(S): Candida albicans 
2015-04-01 | E-GEOD-65396 | biostudies-arrayexpress
TranscriptomicsIdentification and characterization of potent, broad-spectrum antifungal compounds using a yeast reporter bioassay.
New antifungal drugs are urgently needed due to the currently limited selection, the emergence of drug resistance, and the toxicity of several commonly used drugs. To identify drug leads, we screened small molecules using a Saccharomyces reporter bioassay in which the yeast heterologously expresses...
ORGANISM(S): Candida albicans 
2012-04-30 | E-GEOD-35105 | biostudies-arrayexpress
ProteomicsInhibiting Mrt4-rRNA interaction with fumaramidmycin-based derivatives as an unexploited antifungal strategy
The rise of drug resistance and limitations of current antifungal treatments highlight the urgent need for innovative antifungal strategies. Here we present the development of cis-fumaramidmycin-derived analogues as a novel chemotype inhibiting the interactions of ribosome assembly factor Mrt4 with ...
ORGANISM(S): Candida albicans (Yeast) 
2026-04-27 | PXD068797 | Pride
Invasive fungal infections Protein-rna interaction covalent inhibitors Fumaramidmycin derivatives Ribosome assembly factor mrt4 Antifungal target identification 
UnknownAn integrated approach for identification and target validation of antifungal compounds active against Erg11p.
Not available
S-EPMC3421618 | biostudies-literature
Sort   by:  
 Page size